Chugai appoints new US CMO
This article was originally published in Scrip
Executive Summary
Chugai Pharma USA (CPUSA) a wholly owned subsidiary of Chugai Pharmaceutical, a Tokyo, Japan-based member of the Roche Group, has named Dr Athos Gianella-Borradori chief medical officer, CPUSA. Dr Gianella-Borradori has more than 20 years' experience in international drug research. His prior roles include senior positions in research and development at Novartis (Switzerland), Crucell (The Netherlands), Bavarian Nordic (Germany), Cyclacel (United Kingdom), Merck Serono (Switzerland) and Clavis Pharma (Norway).
You may also be interested in...
Ovid Therapeutics: Seeking Innovation In Epilepsy Treatment
Rising Leader Julia Tsai wants to see Ovid Therapeutics become a market leading epilepsy company that listens to the needs of patients and develops innovative drugs to treat a spectrum of epileptic indications and symptoms.
Synaffix’s Serial Dealmaker On ADC Platform Success And Expanding Into Gene Therapy
Anthony DeBoer, head of business development at Synaffix, joined the company in 2014 and has helped develop a platform technology business model in the antibody drug conjugate space, where Synaffix has become one of the leading technology providers enabling best-in-class therapeutic candidates.
In Vivo's 2023 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fourth edition of In Vivo's Rising Leaders series.